Growth Metrics

Trinity Biotech (TRIB) Equity Average (2021 - 2022)

Trinity Biotech recorded quarterly Equity Average of $2.2 million in Q4 2022, down 80.15% quarter-over-quarter from $11.2 million in Q3 2022, and up 807.74% year-over-year from $245500.0 in Q4 2021.

Trinity Biotech's Equity Average history runs 2 years deep, the most recent figure standing at $2.2 million for Q4 2022.

  • In Q4 2022, Equity Average rose 807.74% year-over-year to $2.2 million; the TTM figure through Dec 2022 stood at $2.2 million (up 807.74% YoY), while the FY2025 annual figure was -$53.6 million, down 81.23% from the prior year.
  • Equity Average came in at $2.2 million for Q4 2022 at Trinity Biotech, down from $11.2 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $11.2 million in Q3 2022 to a low of -$3.3 million in Q1 2022.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Equity Avg. (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn 52.42 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn 22.70 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn 49.03 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn 25.17 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn 10.33 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn 2.85 Bn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn 10.53 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn 7.18 Bn
10 Trinity Biotech 28,000.00 -5.11 Mn - -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2022 2.23 Mn
Sep 30, 2022 11.23 Mn
Jun 30, 2022 4.77 Mn
Mar 31, 2022 -3.30 Mn
Dec 31, 2021 245,500.00
Sep 30, 2021 157,000.00
Jun 30, 2021 -311,500.00
Mar 31, 2021 -662,500.00